Dermata Therapeutics, Inc. Common Stock vs. Johnson & Johnson
Dermata Therapeutics, Inc. Common Stock and Johnson & Johnson are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| DRMA | JNJ | |
|---|---|---|
| Market Cap | $5.87 million | $627.42 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | — | $21.04 billion |
JNJ leads on 1 of 1 size & scale factors.
Valuation
| DRMA | JNJ | |
|---|---|---|
| P/E Ratio | — | 30.20 |
| Price / Book | — | 7.38 |
| Price / Sales | — | 6.41 |
DRMA and JNJ split the valuation factors evenly.
Profitability
| DRMA | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | — | 24.76% |
DRMA and JNJ split the profitability factors evenly.
Dividend
| DRMA | JNJ | |
|---|---|---|
| Dividend Yield | — | 2.06% |
| Payout Ratio | — | 62.18 |
DRMA and JNJ split the dividend factors evenly.
Risk & Sentiment
| DRMA | JNJ | |
|---|---|---|
| Short Interest | 0.40% | 0.67% |
DRMA leads on 1 of 1 risk & sentiment factors.
Dig deeper: DRMA overview, DRMA financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.